Immunome's experimental drug meets main goal in late-stage study
15/12/2025 12:12
Dec 15 (Reuters) - Immunome IMNM.O said on Monday its experimental drug met main goal in a late-stage study for patients with a rare type of tumor. (Reporting by Siddhi Mahatole in Bengaluru) ((siddhi.mahatole@thomsonreuters.com;))
Recent news on Immunome
See all newsBrief: Immunome - Enters Amendment No. 4 To License Agreement With Bristol-Myers Squibb Company On Oct 2, 2026
US STOCKS ON THE MOVE-Cardinal Health, nVent, Acuity
U.S. STOCKS ON THE MOVE-Cardinal Health, Fervo Energy, Rocket Lab
U.S. STOCKS ON THE MOVE-Progress Software, Vicor Corp, Accenture
Immunome climbs as Stifel initiates coverage